Announcements Trials
Browse Landscape

Status

Completed 5Active not recruiting 4Recruiting 3Terminated 1Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 3Lymphoma, Non-Hodgkin 1Leukemia, Plasma Cell 1Leukemia, B-Cell 1Infections 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × idecabtagene vicleucel × Clear all
NCT06357754 2026-01-22

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Bristol-Myers Squibb

Recruiting
50 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell

NCT06855121 2025-03-03

NIMMS

St. Olavs Hospital

Recruiting
400 enrolled
Other hematologic neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Infections, Leukemia, Plasma Cell, Multiple Myeloma

NCT06698887 2024-12-13

A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

Bristol-Myers Squibb

Recruiting
15 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡